The Chinese fast-fashion retailer has been at the centre of controversy over its London IPO, and now it faces new challenges from the US and the UK ...
Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback